. Credit: CDC
As health workers in New Jersey, Illinois and New York state struggle to contain the spread of a highly infectious and deadly fungus, the Bath Israel Deaconess Medical Center (BIDMC) microbiologists have shown that a combination of antifungal and anti-bacterial drugs may be an effective weapon against recently discovered multi-resistance, Candida auris ( C. auris ).
BIDMC Thea Brennan-Krohn presented the report on Friday, June 21
, 2019 at ASM Microbe 2019, the annual meeting of the American Society of Microbiology. "Few treatment options are available for patients infected with Candida auris which causes invasive, life-threatening infections, usually in patients who are already critically ill or have a compromised immune system," said Brennan-Crohn , Ph.D. Research Laboratory at James E. E. Kirby, Director of the Clinical Microbiology Laboratory at BIDMC. "He has a disturbing tendency to spread from patient to patient and to survive on surfaces in rooms, leading to the emergence of hospital outbreaks."
First discovered in Japan in 2009
C. auris was found in patients in more than 20 countries and, from April 2019, 643 Americans were in 11 US countries, according to US Centers for Control and Prevention of Diseases (CDC). At present, most cases of C. auris are resistant to at least one antifungal drug with about one-third impermeable to two or more
In order to identify new treatment approaches for [A] Brennan-Krohn and colleagues used a modified inkjet printer – a method developed for rapid and unified antimicrobial screening at the Kirby Laboratory – for testing three antifungal drugs, one of each of the major antifungal classes combined with two antibacterial antibiotics, which by themselves no activity against fungal infections
Using the inking technique of dividing homozygous samples from
C. auris into each of the 96 wells in a standard laboratory assay plate, Brennan-Krohn tested 10 combinations against 10 strains of C. auris A difficult process that would take at least 50 hours if done by hand. It took less than two hours with the Brennan-Krohn inkjet jar to find three new combinations of antifungal and antibacterial drugs that showed activity against this subtle new pathogen.
Using a different method known as the time killing test, Brennan-Krohn showed that two of the antibacterial-antimycotic treatments not only prevented growth, but also managed to kill some of the tested strains
While drugs have not yet been tested in combination in people infected with
C. auris all drugs evaluated by Brennan-Krohn – the antifungicides amphotericin and caspofungin and the antibacterials minocycline and rifampin – are approved by the FDA antibiotics that are currently used in patients with different infections. If drugs combine the power to inhibit or kill C. auris which they demonstrate in the laboratory, it is confirmed in human studies, which may mean doctors who care for C. auris ] infections already have access to effective treatment options.
CDC: Superbug's Flu is painful by 600 Americans
Bath Israel Deaconess Medical Center
The combination of drugs can fight a lethal drug-resistant sponge (2019, June 22)
restored on 22 June 2019
This document is subject to copyright. Apart from any honest work for the purposes of private research or research, no
may be reproduced without written permission. Content is provided for information purposes only.